Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of Dipivefrin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 5/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 3/20 | 0.47 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.47 |
| ▸ | ADRB3 known ✓ | P13945 | 3/20 | 0.47 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.47 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.47 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.47 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.47 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | LMNA | P02545 | 2/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | BLM | P54132 | 4/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dipivefrin SCHEMBL5275338 | 1.00 | ADRB2 (1.00) | ADRB2HIF1AALDH1A1CYP3A4LMNA | |
| Dipivefrin SCHEMBL18687014 | 1.00 | ADRB2 (1.00) | ADRB2HIF1AALDH1A1CYP3A4LMNA | |
| Dipivefrin SCHEMBL8071336 | 1.00 | ADRB2 (1.00) | ADRB2HIF1AALDH1A1CYP3A4LMNA | |
| Dipivefrin SCHEMBL41350 | 1.00 | ADRB2 (1.00) | ADRB2HIF1AALDH1A1CYP3A4LMNA | |
| Dipivefrin SCHEMBL29710905 | 0.99 | HIF1A (1.00) | ADRB2HIF1AALDH1A1CYP3A4LMNA | |
| Dipivefrin SCHEMBL20673238 | 0.99 | HIF1A (1.00) | ADRB2HIF1AALDH1A1CYP3A4LMNA | |
| Dipivefrin SCHEMBL24714 | 0.99 | HIF1A (1.00) | ADRB2HIF1AALDH1A1CYP3A4LMNA | |
| Dipivefrin SCHEMBL24713 | 0.99 | HIF1A (1.00) | ADRB2HIF1AALDH1A1CYP3A4LMNA | |
| Dipivefrin SCHEMBL3053588 | 0.96 | HIF1A (0.95) | ADRB2HIF1AALDH1A1CYP3A4LMNA | |
| Dipivefrin SCHEMBL8468680 | 0.91 | HIF1A (0.86) | ADRB2HIF1AALDH1A1CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1400 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387363-A1 | LIQUID EPINEPHRINE PRODRUG FORMULATIONS AND LIQUID EPINEPHRINE FORMULATIONS | INSIGNIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | claimed |
| CN-119677539-A | Combination therapy for modulating lipid production | 俄亥俄州创新基金会 | 2025-03-21 | — | — | CN | claimed |
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | Insignis Therapeutics, Inc. | 2025-01-02 | — | — | US | claimed |
| CN-117797151-A | Quinoline derivatives combined with chemotherapeutics for treating non-small cell lung cancer | 正大天晴药业集团股份有限公司 | 2024-04-02 | — | — | CN | claimed |
| CN-111565716-B | Method of using dipivefrin | 因斯格尼斯疗法有限公司 | 2023-06-09 | — | — | CN | claimed |
| WO-2023076477-A2 | ORALLY DISINTEGRATING TABLET FOR EPINEPHRINE PRODRUG FORMULATIONS | Insignis Therapeutics, Inc. (US) | 2023-05-04 | — | — | WO | claimed |
| US-20220193010-A1 | METHODS OF USING DIPIVEFRIN | INSIGNIS THERAPEUTICS INC (US) | 2022-06-23 | — | — | US | claimed |
| US-20220071898-A1 | DIPIVEFRIN ORALLY DISINTEGRATING TABLET FORMULATIONS | INSIGNIS THERAPEUTICS INC (US) | 2022-03-10 | — | — | US | claimed |
| EP-3930685-A1 | DIPIVEFRIN ORALLY DISINTEGRATING TABLET FORMULATIONS | INSIGNIS THERAPEUTICS, INC. (US) | 2022-01-05 | — | — | EP | claimed |
| US-11213496-B2 | Methods of using dipivefrin | Insignis Therapeutics, Inc. (US) | 2022-01-04 | — | — | US | claimed |
| US-5858996-A | ACRYLIC POLYMER, AMINO TRI(LOWER ALKYLENE PHOSPHONIC ACID) CHELATING AGENT; OPHTHALMIC DELIVERY | CIBA VISION CORPORATION (US) | 1999-01-12 | — | — | US | claimed |
| CN-1196676-A | Ophthalmic compositions containing cyclodextrins and quaternary ammonium compounds | NOVARTIS AG (CH) | 1998-10-21 | — | — | CN | claimed |
| EP-0862414-A1 | OPHTHALMIC COMPOSITIONS CONTAINING CYCLODEXTRINS AND QUATERNARY AMMONIUM COMPOUNDS | Novartis AG (CH) | 1998-09-09 | — | — | EP | claimed |
| EP-0844868-A1 | COMPOSITIONS INCLUDING O-CARBOXYALKYL CHITOSAN AND METHODS OF USE IN OPHTHALMICS | Novartis AG (CH) | 1998-06-03 | — | — | EP | claimed |
| EP-0833609-A1 | COMPOSITIONS AND METHODS FOR STABILIZING POLYMERS | Novartis AG (CH) | 1998-04-08 | — | — | EP | claimed |
| US-5733938-A | TREATMENT OF GLAUCOMA | ALLERGAN (US) | 1998-03-31 | — | — | US | claimed |
| WO-1997010805-A1 | OPHTHALMIC COMPOSITIONS CONTAINING CYCLODEXTRINS AND QUATERNARY AMMONIUM COMPOUNDS | NOVARTIS AG (CH) | 1997-03-27 | — | — | WO | claimed |
| WO-1997006782-A1 | COMPOSITIONS INCLUDING O-CARBOXYALKYL CHITOSAN AND METHODS OF USE IN OPHTHALMICS | NOVARTIS AG (CH) | 1997-02-27 | — | — | WO | claimed |
| WO-1997000669-A1 | COMPOSITIONS AND METHODS FOR STABILIZING POLYMERS | NOVARTIS AG (CH) | 1997-01-09 | — | — | WO | claimed |
| US-5227372-A | METHOD FOR RETAINING OPHTHALMOLOGICAL AGENTS IN OCULAR TISSUES | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1993-07-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220071898-A1 | DIPIVEFRIN ORALLY DISINTEGRATING TABLET FORMULATIONS | ADGRF1, DDR1, AGER | ADRB2 11/4885ADRB1 4/4885ADRA2A 95/4885 |
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | ADRB2 138/4885ADRB1 114/4885ADRA2A 155/4885 |
| US-20220193010-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | ADRB2 138/4885ADRB1 114/4885ADRA2A 155/4885 |
| US-11213496-B2 | Methods of using dipivefrin | QDPR, DNPEP, DPEP1 | ADRB2 138/4885ADRB1 114/4885ADRA2A 155/4885 |
| US-20250387363-A1 | LIQUID EPINEPHRINE PRODRUG FORMULATIONS AND LIQUID EPINEPHRINE FORMULATIONS | ADRB3, ADRB2, ADRB1 | ADRB2 2/4885ADRB1 3/4885ADRA2A 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.